Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

This study has been terminated.
(This study was terminated in November 2008 due to "a business decision (resources)".)
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: September 18, 2008
Last updated: July 10, 2014
Last verified: July 2014
This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone marrow or blood of another person.

Condition Intervention Phase
Drug: E5564
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Safety and assessments will be done daily. [ Time Frame: Performed daily through Day 28, with follow-up every other week to Day 100 and at 1 year post-transplant. ]

Enrollment: 30
Study Start Date: September 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: E5564
Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
Other Name: Eritoran

Detailed Description:
Please note: in the original protocol, the study phase is listed as "Phase Ib", although the Official Title reads "Phase I".

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must meet all of the inclusion criteria outlined below in order to be eligible to participate in this study:

  1. Adult subjects (aged 18 to 55 years old) undergoing or scheduled to undergo myeloablative conditioning and allogeneic BMT, or stem cells from matched donors.
  2. Subjects using either busulfan or total body irradiation (TBI) containing regimens for BMT for the treatment of malignant and nonmalignant diseases. For example:

    • Cyclophosphamide and Total Body Irradiation (CY-TBI) with a TBI dose of at least 1200 cGy of fractionated TBI
    • Etoposide and Total Body Irradiation (VP16-TBI) with a TBI dose of at least 1200 cGy of fractionated TBI
    • Busulfan and cyclophosphamide (BU-CY) with at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state.
  3. Leukemia patients with:

    • acute myelogenous leukemia (AML)
    • acute lymphoblastic leukemia (ALL) in first or subsequent complete remission
    • chronic myelogenous leukemia (CML) in first or subsequent chronic phase or in accelerated phase
    • myelodysplastic syndrome (MDS) patients.


    Subjects with non-Hodgkin's lymphoma who are in complete remission as determined by physical exam, CT and PET scans, and are otherwise considered candidates for allogeneic BMT as judged by the treating institution

  4. Available matched related CD34+ stem cells (target cell dose between 2 x 10^6/kg and 10 x 10^6/kg (actual body weight)) for transplantation (matched at 6/6 HLA at Class I HLA-A and B and Class II HLA-DRBI).
  5. Sex distribution: men or nonpregnant women. Women of childbearing potential must have a negative serum β-human chorionic gonadotropin (hCG) or urine assay prior to eritoran treatment or prior to the beginning of conditioning treatment. Menopausal women must have been amenorrheic for at least 12 months.
  6. Race: any.
  7. Has signed informed consent before any study-specific procedures are performed.

Exclusion Criteria:

  1. Unwilling or unable to agree to be fully evaluated for all follow-up visits. The subject or subject's representative and the study staff should agree to perform all study assessments even if the subject is discharged from the hospital.
  2. Seropositive for human immunodeficiency virus (HIV); testing is not needed if already performed (documentation required) as part of screening for conditioning treatment.
  3. Subjects with a documented or possible systemic infection, or suspected of having a medically significant viral, bacterial, or fungal infection at the beginning of treatment on Day -3.
  4. Have taken any investigational medications (ie, not approved by the FDA for any indication) within the 30-day period prior to enrollment into the study.
  5. Karnofsky Performance Status (KPS) <60%.
  6. Have previously received a bone marrow or stem cell transplant.
  7. Are to receive T-cell depleted BMT or stem cell infusions.
  8. Are pregnant or lactating.
  9. Known sensitivity to eritoran or its excipients.
  10. Prior malignancies treated with a curative intent of < 5 years will not be allowed. Previously treated cancer with a curative intent of > 5 years will be allowed.
  11. Legal incapacity.
  12. Any of the following laboratory parameters within 2 days prior to the beginning of treatment on Day -3:

    • direct bilirubin ≥ 2x ULN
    • liver function tests (ALT or AST) with values ≥ 3x ULN
    • serum creatinine ≥ 2x ULN
  13. Subjects who are enrolled in other interventional, investigational protocols. As aGvHD is likely to only occur after treatment with eritoran is completed, investigational treatments for Grades III and IV aGvHD may be allowed and should be discussed with the Sponsor.
  14. Subjects with a history of or with current pulmonary disease with forced vital capacity (FVC) or forced expiratory volume in 1 second (FEV1) < 60% predicted (corrected for hemoglobin).
  15. Subjects with a history of a cardiac ejection fraction < 45%, or with marked screening or baseline prolongation QT/QTc interval (QTc interval > 470 mSec).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00756912

United States, Ohio
Case Western Reserve University School of Medicine
Cleveland, Ohio, United States, 44106-7728
Sponsors and Collaborators
Eisai Inc.
Principal Investigator: Kenneth Cooke Case Western Reserve University School of Medicine
  More Information

Responsible Party: Eisai Inc. Identifier: NCT00756912     History of Changes
Other Study ID Numbers: E5564-A001-102
Study First Received: September 18, 2008
Last Updated: July 10, 2014

Keywords provided by Eisai Inc.:
graft versus leukemia
graft vs. host disease
MD2 (endotoxin binding-protein)
undergo allogeneic BMT
therapy processed this record on May 25, 2017